Arvest Bank Trust Division Purchases Shares of 59,127 DexCom, Inc. $DXCM

Arvest Bank Trust Division purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 59,127 shares of the medical device company’s stock, valued at approximately $3,713,000.

Other large investors also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of DexCom during the fourth quarter valued at $483,356,000. AQR Capital Management LLC lifted its holdings in shares of DexCom by 597.8% during the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after purchasing an additional 2,658,158 shares in the last quarter. Employees Provident Fund Board acquired a new position in shares of DexCom in the fourth quarter valued at approximately $145,352,000. J. Stern & Co. LLP increased its holdings in DexCom by 2,114.8% during the 4th quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock worth $106,323,000 after purchasing an additional 1,529,641 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in DexCom by 271.4% during the 1st quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock worth $129,699,000 after acquiring an additional 1,509,219 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. TD Cowen reaffirmed a “buy” rating and set a $95.00 price target (up from $75.00) on shares of DexCom in a research report on Wednesday, June 10th. Barclays reissued an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Citigroup reiterated a “buy” rating and set a $84.00 target price (up from $79.00) on shares of DexCom in a research note on Thursday, May 28th. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Finally, Robert W. Baird set a $80.00 price objective on DexCom in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $85.36.

Insider Buying and Selling at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This represents a 3.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $74.13, for a total value of $364,052.43. Following the completion of the transaction, the executive vice president owned 95,450 shares of the company’s stock, valued at $7,075,708.50. This represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,750 shares of company stock worth $5,163,241 over the last three months. 0.28% of the stock is owned by corporate insiders.

DexCom Stock Performance

DexCom stock opened at $74.75 on Wednesday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock has a market cap of $28.84 billion, a PE ratio of 31.94, a P/E/G ratio of 1.25 and a beta of 1.45. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The business’s 50-day moving average price is $71.75 and its two-hundred day moving average price is $68.86.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the company posted $0.32 EPS. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. As a group, analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.